Coronary heart disease secondary prevention beta-blockers
|
Coronary heart disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coronary heart disease secondary prevention beta-blockers On the Web |
|
American Roentgen Ray Society Images of Coronary heart disease secondary prevention beta-blockers |
|
FDA on Coronary heart disease secondary prevention beta-blockers |
|
CDC on Coronary heart disease secondary prevention beta-blockers |
|
Coronary heart disease secondary prevention beta-blockers in the news |
|
Blogs on Coronary heart disease secondary prevention beta-blockers |
|
Risk calculators and risk factors for Coronary heart disease secondary prevention beta-blockers |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Beta Blockers
ACC / AHA 2011 Guidelines - Coronary Heart Disease - Secondary Prevention with Beta Blockers (DO NOT EDIT) [1]
| Class I |
| "1. β-Blocker therapy should be used in all patients with left ventricular systolic dysfunction (ejection fraction ≤40%) with heart failure or prior myocardial infarction, unless contraindicated. (Use should be limited to carvedilol, metoprolol succinate, or bisoprolol, which have been shown to reduce mortality.) (Level A)" |
| "2.β-Blocker therapy should be started and continued for 3 years in all patients with normal left ventricular function who have had myocardial infarction or ACS. (Level B)" |
| Class IIa |
|
"1. It is reasonable to continue β-blockers beyond 3 years as chronic therapy in all patients with normal left ventricular function who have had myocardial infarction or ACS. (Level B)" |
|
"2. It is reasonable to give β-blocker therapy in patients with left ventricular systolic dysfunction (ejection fraction ≤40%) without heart failure or prior myocardial infarction.(Level C)" |
| Class IIb |
|
"1. β-Blockers may be considered as chronic therapy for all other patients with coronary or other vascular disease. (Level C)" |
References
- ↑ Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA; et al. (2011). "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation". Circulation. 124 (22): 2458–73. doi:10.1161/CIR.0b013e318235eb4d. PMID 22052934.